ESMO Award for Translational Research
The Award is presented to candidates who are internationally recognised for outstanding achievements in translational research.
The award consists of the opportunity to give a scientific lecture, a prize and free registration, free accommodation and reimbursement of travel expenses to ESMO 2017 Congress in Madrid, Spain.
Nomination closed 4 April 2017
In order to be considered for the award, a nominee must:
- Be an individual (institutions and organisations are not eligible) who has made an impact in cancer science throughout their career and are recognised for their outstanding contribution to translational medicine, which has led to successful application in the clinic.
- Have published research results in highly cited peer-reviewed journals
- Be an oncology professional, medical or clinical oncologist
- Be an ESMO member
- Have not previously received an analogous award (the previous Hamilton Fairley Award) from ESMO
- Not be a current or recent (last two years) member of either the ESMO Executive Board or the ESMO Fellowship and Award Committee
Nomination and selection process
Nominations may be made by ESMO members* in good standing, and within the stated deadline via the online form established for this purpose. You will be asked to sign in to your myESMO account in order to fill in the nomination form. Members cannot nominate themselves.
All nominations will be evaluated by the ESMO Fellowship and Award Committee. After careful deliberations by the committee, its recommendations are forwarded to the ESMO Executive Board for final consideration and selection.
Previous Hamilton Fairley Awards (now replaced by the ESMO Award for Translational Research)
2016 – Carlos Caldas, UK
Carlos Caldas’ research focus is the functional genomics of breast cancer and its biological and clinical implications. His laboratory redefined the molecular taxonomy of breast cancer, revealing novel subtypes and their respective drivers. It also completed microRNA (miRNA) profiling of 1,300 of the same tumours, which uncovered a new role for miRNAs as modulators of the immune response in a subset of breast cancers.
Caldas’ group co-led seminal studies defining the clonal heterogeneity of triple negative breast cancers and the patterns of whole-genome oestrogen receptor binding in primary tumours, which revealed new biology. Finally, his group co-led studies that established circulating tumour DNA as a monitoring biomarker and a liquid biopsy to unravel therapy resistance. More recently Caldas’ laboratory has been developing the use of patient-derived tumour explants as a model system for breast cancer.
I feel extremely honored and humbled with receiving this award. In particular, as a Portuguese physician-scientist based in the UK. I would like to acknowledge all current and past members of my group as well as my colleagues at the Cambridge Cancer Centre and at Addenbrooke’s Hospital. I would also like to acknowledge the support I have received from Cancer Research UK, which has funded most of the work in my group. Without them I would have never even been considered for this prestigious award.
I feel extremely honoured and humbled with receiving this award. In particular, as a Portuguese physician-scientist based in the UK. I would like to acknowledge all current and past members of my group as well as my colleagues at the Cambridge Cancer Centre and at Addenbrooke’s Hospital. I would also like to acknowledge the support I have received from Cancer Research UK, which has funded most of the work in my group. Without them I would have never even been considered for this prestigious award.
Carlos Caldas, 2016 ESMO Hamilton Fairley Award Award winner
Caldas has been Professor of Cancer Medicine at the University of Cambridge, UK, since 2002. He is Head of the Breast Cancer Functional Genomics Laboratory at the Cancer Research UK Cambridge Institute, Honorary Consultant Medical Oncologist at Addenbrooke’s Hospital, Lead of the Cambridge Experimental Cancer Medicine Centre, and Director of the Breast Cancer Programme at the Cambridge Cancer Centre.
On behalf of the ESMO Fellowship and Award Committee, Christoph Zielinski said: “Prof. Carlos Caldas has excelled in molecular analyses and its implications in breast cancer where he has analysed an abundance of genomic and transcriptomic landscapes leading to a vastly ameliorated insight into the biology of the disease. Besides having published almost 400 original contributions on the topic, his research achievements have been published in such eminent journals as Nature, the New England Journal of Medicine, Oncogene and Nature Medicine.”
- 2015 - Cornelius Punt, The Netherlands
- 2014 - Heikki Joensuu, Finland
- 2013 - Roger Stupp, Switzerland
- 2012 – Jean-Yves Blay, France
- 2011 - Rafael Rosell, Spain
- 2010 - Bengt Glimelius, Sweden
- 2009 - T.Andrew Lister, United Kingdom
- 2008 - Yosef Yarden, Israel
- 2006 - V. Diehl, Germany
- 2004 - B.A.J. Ponder, United Kingdom
- 2002 - A. Levitzki, Israel
- 2000 - P. Borst, The Netherlands
- 1998 - T. Tursz, France
- 1996 - A. de la Chapelle, Finland
- 1994 - B. Coiffier, France
- 1992 - H.M. Pinedo, The Netherlands
- 1990 - R. Mertelsmann, Germany
- 1988 - G. Klein, Sweden
*All ESMO members are eligible to nominate candidates with the exception of student members (undergraduate medical and science students)